全文获取类型
收费全文 | 2235篇 |
免费 | 104篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 130篇 |
妇产科学 | 51篇 |
基础医学 | 167篇 |
口腔科学 | 91篇 |
临床医学 | 186篇 |
内科学 | 531篇 |
皮肤病学 | 89篇 |
神经病学 | 205篇 |
特种医学 | 120篇 |
外科学 | 349篇 |
综合类 | 16篇 |
预防医学 | 45篇 |
眼科学 | 60篇 |
药学 | 55篇 |
中国医学 | 1篇 |
肿瘤学 | 240篇 |
出版年
2024年 | 2篇 |
2023年 | 84篇 |
2022年 | 122篇 |
2021年 | 121篇 |
2020年 | 154篇 |
2019年 | 86篇 |
2018年 | 62篇 |
2017年 | 90篇 |
2016年 | 106篇 |
2015年 | 100篇 |
2014年 | 183篇 |
2013年 | 151篇 |
2012年 | 128篇 |
2011年 | 89篇 |
2010年 | 137篇 |
2009年 | 126篇 |
2008年 | 97篇 |
2007年 | 83篇 |
2006年 | 78篇 |
2005年 | 57篇 |
2004年 | 47篇 |
2003年 | 38篇 |
2002年 | 23篇 |
2001年 | 34篇 |
2000年 | 28篇 |
1999年 | 35篇 |
1998年 | 13篇 |
1997年 | 13篇 |
1996年 | 9篇 |
1995年 | 15篇 |
1994年 | 3篇 |
1993年 | 5篇 |
1992年 | 3篇 |
1991年 | 9篇 |
1990年 | 2篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1984年 | 3篇 |
1982年 | 3篇 |
1978年 | 1篇 |
排序方式: 共有2346条查询结果,搜索用时 17 毫秒
51.
52.
53.
54.
55.
Bone marrow aspirations in oncological patients: experience from an in-house standard in paediatrics
Sauer Harald Graeber Stefan Lieser Ulla Foell Juergen 《Wiener Medizinische Wochenschrift》2019,169(3-4):82-86
Wiener Medizinische Wochenschrift - Nearly all paediatric patients require deep sedation when undergoing bone marrow aspiration (BMA). We analyzed the data from our protocols documented in... 相似文献
56.
Changing trends in penetrating keratoplasty indications at a tertiary eye care center in Budapest, Hungary between 2006 and 2017 下载免费PDF全文
Milán Tamás Pluzsik Gábor Tóth Jeannette Tóth András Matolcsy Achim Langenbucher Agnes Kerényi Zoltán Zsolt Nagy Nóra Szentmáry 《国际眼科》2020,13(11):1814-1819
AIM: To analyse the changing trends in penetrating keratoplasty (PKP) indications. METHODS: This retrospective study included all patients with PKP between 2006 and 2017. Patients were classified using histological diagnoses. Our groups were more than 10 various keratopathies. Additionally, two different time-periods (2006-2012 and 2013-2017) were analysed. Results: Totally 1721 histological analyses of 1214 patients were available for review. The diagnoses were pseudophakic or aphakic bullous keratopathy in 487 (28.3%), regraft in 443 (25.7%), acute necrotizing and ulcerative keratitis in 313 (18.2%), corneal scar in 153 (8.9%), keratoconus in 140 (8.1%). Fuchs’ dystrophy in 61 (3.5%), corneal dystrophy other than Fuchs’ in 46 (2.7%), other diagnoses in 44 (2.6%) and failed endothelial keratoplasty graft in 34 (2.0%) cases. From the first to the second analysed time-period, incidence of acute necrotizing and ulcerative keratitis, corneal scar, Fuchs’ dystrophy increased (P≤0.032 for all) and incidence of keratoconus significantly decreased (P=0.015). Conclusion: Pseudophakic or aphakic bullous keratopathy is the leading indication for PKP, followed by regraft and acute necrotizing and ulcerative keratitis. 相似文献
57.
《Journal of cystic fibrosis》2020,19(2):284-291
BackgroundShortcomings of inhaled antibiotic treatments for Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF) include poor drug penetration, inactivation by sputum, poor efficiency due to protective biofilm, and short residence in the lung.MethodsEligible patients with forced expiratory volume in 1 s (FEV1) ≥25% of predicted value at screening and CF with chronic P. aeruginosa infection were randomly assigned to receive 3 treatment cycles (28 days on, 28 days off) of amikacin liposome inhalation suspension (ALIS, 590 mg QD) or tobramycin inhalation solution (TIS, 300 mg BID). The primary endpoint was noninferiority of ALIS vs TIS in change from baseline to day 168 in FEV1 (per-protocol population). Secondary endpoints included change in respiratory symptoms by Cystic Fibrosis Questionnaire-Revised (CFQ-R).ResultsThe study was conducted February 2012 to September 2013. ALIS was noninferior to TIS (95% CI, −4.95 to 2.34) for relative change in FEV1 (L) from baseline. The mean increases in CFQ-R score from baseline on the Respiratory Symptoms scale suggested clinically meaningful improvement in both arms at the end of treatment in cycle 1 and in the ALIS arm at the end of treatment in cycles 2 and 3; however, the changes were not statistically significant between the 2 treatment arms. Treatment-emergent adverse events (TEAEs) were reported in most patients (ALIS, 84.5%; TIS, 78.8%). Serious TEAEs occurred in 17.6% and 19.9% of patients, respectively; most were hospitalisations for infective pulmonary exacerbation of CF.ConclusionsCyclical dosing of once-daily ALIS was noninferior to cyclical twice-daily TIS in improving lung function.ClinicalTrials.gov Identifier: NCT01315678 相似文献
58.
59.
60.